TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03659903

Intervention type: PROCEDURE
Intervention: pancreaticoduodenectomy
Description: pancreaticoduodenectomy

Intervention type: PROCEDURE
Intervention: pancreaticoduodenectomy
Description: pancreaticoduodenectomy
Study: NCT04195438

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CO Testing Pre/Post Hepatic Resection
Description: Monitor CO in exhaled air of patients before liver resection, at 4 hours and 24 hours after PH

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ABG Testing Pre/Post Hepatic Resection
Description: Monitor carboxyhemoglobin(COHb) in the arterial blood gas of patients before liver resection at 4 hours and 24 hours after PH

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT Evaluations
Description: Analyze the relationship between CO production and the extent of hepatic resection assessed by computed scans liver volumetric study at one and three months after PH, size and weight of the resected specimen and operative report
Study: NCT04449393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emdogain® FL
Description: Emdogain® FL is an enamel matrix derivative intended for subgingival and topical application in conjunction with scaling and root planing procedures to provide regeneration of tooth support lost due to periodontal disease. Emdogain® FL has been shown to be effective in residual pockets with probing depths from 5mm to 9mm with no furcation involvement in patients with adequate plaque control. Emdogain® FL has also been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing procedures as part of non-surgical periodontal therapy involves mechanical removal of dental plaque and calculus using curettes and sonic scalers.
Study: NCT00929773

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia PL2000 Laser
Description: Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser
Description: Inactive laser light.
Study: NCT02154490

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Intervention: Palbociclib
Description: Given PO

Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Intervention: Rilotumumab
Description: Given IV

Intervention type: DRUG
Intervention: Talazoparib
Description: Given PO

Intervention type: DRUG
Intervention: Taselisib
Description: Given PO
Study: NCT04275271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Skill centered Protocol Training based on IMB model
Study: NCT04172415

Intervention type: OTHER
Intervention: Retrospective cohort
Description: Chart Review
Study: NCT00570505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAP-BAND System
Description: Reduction of food intake due to creation of smaller stomach pouch
Study: NCT02203032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: 45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
Study: NCT01382303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 400mg three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet three times a day
Study: NCT05837403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma injection
Description: venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin ointment
Description: application of the ointment twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Description: application of the ointment twice daily
Study: NCT02313727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate
Description: intravenous infusion of pamidronate 60 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Description: intravenous infusion of NaCl 0.9% 500 ml
Study: NCT03164317

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
Study: NCT03202355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Appliance Orthodontic Treatment
Description: Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Appliance Orthodontic Treatment
Description: Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse™
Description: Patients carry out daily OrthoPulse™ treatments at home.
Study: NCT00831610

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.
Description: Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)
Description: Bariatric surgery Plastic surgery Abdominoplasty

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)
Description: Bariatric surgery Plastic surgery Abdominoplasty
Study: NCT00996294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biliopancreatic diversion, gastric bypass
Description: biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
Study: NCT03858335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Description: The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
Study: NCT02671890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00792662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard inactive pill.
Study: NCT04068181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion.
Study: NCT03519971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/ Etoposide
Description: Cisplatin/ Etoposide, as per standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin/ Etoposide
Description: Cisplatin/ Etoposide, as per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin/ Paclitaxel
Description: Carboplatin /Paclitaxel, as per standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin/ Paclitaxel
Description: Carboplatin /Paclitaxel, as per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/ Cisplatin
Description: Pemetrexed / Cisplatin, as per standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed/ Cisplatin
Description: Pemetrexed / Cisplatin, as per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/ Carboplatin
Description: Pemetrexed / Carboplatin , as per standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed/ Carboplatin
Description: Pemetrexed / Carboplatin , as per standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation
Description: 5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
Study: NCT01208662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: intravenous or, following protocol amendment, subcutaneous administration
Study: NCT02203032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: 45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: 100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
Study: NCT01208662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: intravenous or, following protocol amendment, subcutaneous administration
Study: NCT02203032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ustekinumab
Description: Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for guselkumab
Description: Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
Study: NCT01208662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cell Transplant
Description: Autologous refers to stem cells that are harvested from the participant to be a source of new blood cells after high-dose chemotherapy with melphalan.
Study: NCT03569748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQOS
Description: IQOS USE FOR 12 WEEKS
Study: NCT02154490

Intervention type: DRUG
Intervention: Taselisib
Description: Given PO

Intervention type: BIOLOGICAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT02194205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMBIVENT HFA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HFA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBIVENT CFC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CFC
Study: NCT03590236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded exposure therapy
Description: Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
Study: NCT00180414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT devices with ventricular rate regulation [VRR] (CE labeled)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT devices with ventricular rate regulation [VRR] (CE labeled)
Study: NCT01824394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nMARQ Navigation Catheters

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NaviStar ThermoCool Catheters
Study: NCT03276884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: amino acid-based infant formula powder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: amino acid-based infant formula powder
Study: NCT02584335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine solution (A)
Description: Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception.
Study: NCT02241785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm
Study: NCT02584335

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution (B)
Description: Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception.
Study: NCT03898141

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PL)
Description: Participants will get deceptive and receive an inert cream (=placebo intervention) that reduces pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dog only (DO)
Description: In the dog intervention a dog will be present during the second measurements. However, participants will only learn the true aims of the presence of the dog after the study (delayed informed consent).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted placebo (AAPL)
Description: Participants receive the placebo intervention in the presence of a dog.
Study: NCT02842918

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manual Therapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Spinal Manual Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Range of Motion

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Spinal Range of Motion
Study: NCT00939250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes and depression intervention
Description: Disease self management for diabetes and depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes intervention
Description: Disease self management for diabetes
Study: NCT00719251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High voltage pulsed current
Description: The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser
Description: Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard nursing care
Description: It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
Study: NCT01915914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
Study: NCT04700202

Intervention type: OTHER
Intervention: Observational
Description: Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP
Study: NCT02867189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: atlas of micro-instrument
Description: Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
Study: NCT02792556

Intervention type: DEVICE
Intervention: Urine pregnancy test
Description: Urine pregnancy test Check Top after transvaginal ultrasound
Study: NCT03569748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-CIG
Description: ELECTRONIC CIGARETTE FOR 12 WEEKS